SCHEMBL4862360

SCHEMBL4862360

Cc1ccc(NC(=N)c2ccccn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.56
NPC1 O15118 10/20 0.53
RAB9A P51151 10/20 0.53
SMN1; SMN2 Q16637 9/20 0.53
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
HTT P42858 3/20 0.53
L3MBTL1 Q9Y468 3/20 0.48
MAPT P10636 5/20 0.48
PKM P14618 2/20 0.48
KMT2A Q03164 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CCR6 P51684 1/20 0.47
GFER P55789 1/20 0.47
MITF O75030 2/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 1/20 0.47
TP53 P04637 1/20 0.47
APP P05067 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14223875 0.85 NPC1 (0.49) KDRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL25393684 0.83 KDR (0.59) KDRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4854729 0.83 KMT2A (0.51) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL14223457 0.83 NPC1 (0.47) KDRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4861195 0.83 RAB9A (0.56) KDRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4860965 0.83 RAB9A (0.52) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL4855888 0.83 RAB9A (0.71) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL4853449 0.83 NPC1 (0.51) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL25394146 0.82 RAB9A (0.46) KDRNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6037590 0.81 KDR (0.78) KDRNPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP KDR 2145/4885NPC1 1563/4885RAB9A 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.